In joint fluid from six patients, the same T cells returned, more inflamed, when immunotherapy arthritis flared again

What the research found

Study (small patient series). Roza Nurieva, Sang T. Kim, and colleagues at MD Anderson and Yale report in Cancer Immunology Research (DOI 10.1158/2326-6066.CIR-25-1639; accepted 29 Jul 2026). A public abstract and an 11 Aug 2026 briefing say joint fluid from six patients was sampled at a first immune-checkpoint-inhibitor arthritis flare and again at a recurrence. Effector CD8 T cells and PD-1-high, CXCL13-high CD4 T cells were enriched versus joint fluid from six people with osteoarthritis who did not have cancer. Of the top 10 expanded clones, 93 percent of the effector CD8 clones and 50 percent of the PD-1-high CD4 clones were shared between the first and second flare. Those cells made more inflammatory signals on the later flare. Six people cannot show who will flare or what to change. Do not stop a cancer immunotherapy because of this headline. Not medical advice.

Evidence level: Human study. A study in people, but an association isn't proof of cause.

Read the original at MD Anderson / Cancer Immunology Research